The management of advanced bladder carcinoma

Area of Science:

• Oncology
• Medical Research

Background:

• Metastatic bladder cancer presents a significant treatment challenge.
• Combination chemotherapy is a key strategy for managing advanced urothelial carcinoma.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a specific combination chemotherapy regimen in patients with metastatic bladder carcinoma.
• To assess response rates and adverse events associated with cis-platinum, doxorubicin hydrochloride, and cyclophosphamide therapy.

Main Methods:

• A cohort of 25 patients with measurable metastatic bladder carcinoma was treated.
• The regimen consisted of cis-platinum (60 mg/m²), doxorubicin hydrochloride (40 mg/m²), and cyclophosphamide (400 mg/m²) administered every 4 weeks.
• Patient selection criteria were strict, focusing on measurable disease parameters.

Main Results:

• An overall response rate of 82% (19 out of 23 evaluable patients) was observed.
• This included 5 complete remissions and 14 partial remissions.
• Common toxicities included myelosuppression, nausea, vomiting, and alopecia; one patient died from septicemia secondary to agranulocytosis.

Conclusions:

• The combination of cis-platinum, doxorubicin hydrochloride, and cyclophosphamide demonstrates high effectiveness against transitional cell carcinoma of the bladder.
• This regimen appears to be a promising therapeutic option for metastatic bladder cancer, with generally manageable side effects.